Prostate Artery Embolization (PAE) has emerged as a novel treatment option for Benign ProstaticHypertrophy (BPH) with clinical efficacy comparable to the current surgical gold standard, transurethral resection of the prostate (TURP). In a multicentric study, 5 patients with high-risk BPH selected from June 2021 to March 2022 underwent PAE to evaluate efficacy, safety and postoperative quality of life after treatment with PAE. Different variables like changes of international prostate symptom score (IPSS), post void residual volume (PVR), maximum urine flow rate (Qmax) and Prostate Volume (PV) were compared before and after operation. PAE was successful in all 4 patients. 1 patient was lost to follow up after 1 month despite of improvement in Qmax. No severe complications were noted in the postoperative patients. The IPSS, PV and PVR levels of the patient at follow up were lower than those before surgery, while the Qmax level was higher than that before procedure. For high-risk BPH patients, PAE is an effective and safe method with good application prospects and fewer complications eliminating need of general anesthesia or hospitalization. However, due to the small sample size in this study, further observation and study is needed to determine its long-term efficacy and safety.

Keywords: Prostate artery embolization, Benign prostatic hypertrophy, transurethral resection of the prostate, clinical efficacy, quality of life